2024-03-29T06:02:51Zhttps://riubu.ubu.es/oai/requestoai:riubu.ubu.es:10259/49652021-11-10T09:38:25Zcom_10259_4725com_10259_5086com_10259_2604col_10259_4726
Liver-specific ablation of insulin-degrading enzyme causes hepatic insulin resistance and glucose intolerance, without affecting insulin clearance in mice
Villa Pérez, Pablo .
Merino, Beatriz
Fernández Díaz, Cristina M. .
Cidad, Pilar
Lobatón, Carmen D.
Moreno, Alfredo
Muturi, Harrison T. .
Ghadieh, Hilda E. .
Najjar, Sonia M. .
Leissring, Malcolm A.
Cózar Castellano, Irene
Perdomo Hernández, Germán M.
nsulin-degrading enzyme
Hepatic insulin resistance
Insulin recepto
Carcinoembryonic antigen-related cell adhesion molecule 1
Endocrinología
Endocrinology
The role of insulin-degrading enzyme (IDE), a metalloprotease with high affinity for insulin, in insulin clearance remains poorly understood. OBJECTIVE: This study aimed to clarify whether IDE is a major mediator of insulin clearance, and to define its role in the etiology of hepatic insulin resistance.
Methods
We generated mice with liver-specific deletion of Ide (L-IDE-KO) and assessed insulin clearance and action.
Results
L-IDE-KO mice exhibited higher (~20%) fasting and non-fasting plasma glucose levels, glucose intolerance and insulin resistance. This phenotype was associated with ~30% lower plasma membrane insulin receptor levels in liver, as well as ~55% reduction in insulin-stimulated phosphorylation of the insulin receptor, and its downstream signaling molecules, AKT1 and AKT2 (reduced by ~40%). In addition, FoxO1 was aberrantly distributed in cellular nuclei, in parallel with up-regulation of the gluconeogenic genes Pck1 and G6pc. Surprisingly, L-IDE-KO mice showed similar plasma insulin levels and hepatic insulin clearance as control mice, despite reduced phosphorylation of the carcinoembryonic antigen-related cell adhesion molecule 1, which upon its insulin-stimulated phosphorylation, promotes receptor-mediated insulin uptake to be degraded.
Conclusion
IDE is not a rate-limiting regulator of plasma insulin levels in vivo
Ministerio de Economía, Industria y Competitividad: SAF2014-58702-C2-1-R and SAF2016-77871-C2-1-R to ICC; SAF2014-58702-C2-2-R and SAF2016-77871-C2-2-R to GP; supported by the EFSD European Research Programme on New Targets for Type 2 Diabetes supported by an educational research grant from MSD to ICC and GP; the National Institutes of Health: R01-DK054254, R01-DK083850 and RO1-HL-112248 to SMN, and R01-GM115617 to MAL; and the American Diabetes Association: Career Development Award 7-11-CD-13 to MAL.
2018-10-11T10:26:09Z
2018-10-11T10:26:09Z
2018-11
info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
0026-0495
http://hdl.handle.net/10259/4965
10.1016/j.metabol.2018.08.001
eng
Metabolism. 2018, V. 88, p. 1-11
https://doi.org/10.1016/j.metabol.2018.08.001
info:eu-repo/grantAgreement/MINECO/SAF2014-58702-C2-1-R
info:eu-repo/grantAgreement/MINECO/SAF2016-77871-C2-1-R
info:eu-repo/grantAgreement/MINECO/SAF2014-58702-C2-2-R
info:eu-repo/grantAgreement/MINECO/SAF2016-77871-C2-2-R
info:eu-repo/grantAgreement/NationalInstitutesofHealth/R01-DK054254
info:eu-repo/grantAgreement/NationalInstitutesofHealth/R01-DK083850
info:eu-repo/grantAgreement/NationalInstitutesofHealth/RO1-HL-112248
info:eu-repo/grantAgreement/NationalInstitutesofHealth/R01-GM115617
Attribution 4.0 International
http://creativecommons.org/licenses/by/4.0/
info:eu-repo/semantics/openAccess
application/pdf
Elsevier